Evaxion to Present One-Year Phase 2 Data on Lead Cancer Vaccine EVX-01 at ESMO 2024

Evaxion Biotech A/S, a clinical-stage TechBio company known for its AI-Immunology™ powered vaccines, has announced the presentation of one-year clinical efficacy Phase 2 data for its lead compound EVX-01. The presentation will take place at the European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona, Spain from September 13-17, 2024. EVX-01 is a personalized vaccine currently under evaluation in patients with advanced melanoma, a type of skin cancer.

Christian Kanstrup, CEO of Evaxion, stated that the selection of their abstract for presentation by the ESMO Congress 2024 Scientific Committee underscores the progress and impact of their work in medical oncology. He highlighted the significance of presenting the one-year Phase 2 clinical efficacy data for their lead pipeline candidate, considering it a major milestone for the company. The event provides an excellent platform to share data with a global audience of experts, researchers, collaborators, and potential partners.

Evaxion’s approach to personalized cancer vaccines leverages its AI-Immunology™ platform, aiming to target the unique genetic makeup of individual tumors. This personalized method is tailored to the patients’ immune systems, potentially enhancing treatment efficacy and improving patient outcomes.

The detailed presentation of the Phase 2 study will be given by Dr. Paola Queirolo, Director, Medical Oncology of Melanoma, Sarcoma, and Rare Tumors at the European Institute of Oncology in Milan, Italy. The presentation is scheduled for September 14 at 12:00 – 13:00 CEST in Hall 6 of the conference venue. The abstract, titled "Phase 2 study of AI-designed personalized neoantigen cancer vaccine, EVX-01, in combination with pembrolizumab in advanced melanoma," is designated Abstract #1084P and Poster #2904 under the Melanoma and other skin tumors track.

The Phase 2 clinical trial of EVX-01 is a self-sponsored, open-label, single-arm, multi-center study conducted in collaboration with Merck Sharp & Dohme LLC. The trial involves leading principal investigators and research centers in Italy and Australia. It aims to evaluate the efficacy and safety of EVX-01 vaccination combined with anti-PD1 therapy KEYTRUDA® (pembrolizumab) in treatment-naive patients with metastatic or unresectable malignant stage III or IV melanoma. The trial is registered under clinical trial ID NCT05309421.

Evaxion Biotech A/S is a pioneering company that uses its AI platform, AI-Immunology™, to develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Their proprietary AI prediction models harness artificial intelligence to decode the human immune system. Evaxion has developed a clinical-stage oncology pipeline of personalized vaccines and a preclinical infectious disease pipeline targeting bacterial and viral diseases with high unmet medical needs. The company is dedicated to transforming patients’ lives by providing innovative and targeted treatment options.